Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia

Supplemental New Drug Application -- submitted through FDA Real-Time Oncology Review program -- is based on positive Phase 3 data in patients aged 70 or youngerRARITAN, N.J., Nov. 8, 2019 -- (Healthcare Sales & Marketing Network)-- The Janssen Pharma...Biopharmaceuticals, Oncology
Janssen Pharmaceutical,Johnson & Johnson, IMBRUVICA, ibrutinib